Profusa Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Lumee Tissue Oxygen Monitoring System Revenue Guidance Annually1.5M
Quarterly Net Loss Quarterly-3.5M
Cash and Cash Equivalents Quarterly400K
Watch Items
- Nasdaq Listing Compliance (Minimum Bid Price and Stockholders' Equity)Trigger: July 6, 2026 deadline to meet specific Capital Market tier requirementsAction: Execute proposed reverse stock split (1-for-5 to 1-for-200 range) authorized at the June 23, 2026 annual meeting to regain bid-price compliance.
- CE Mark Certification for Lumee Oxygen PlatformTrigger: GMED MDR conformity assessment review outcomeAction: Support the ongoing review process following the submission of the comprehensive response package to GMED in June 2026.
- PanOmics Platform Acquisition ClosingTrigger: Stockholder approval of the $30,000,000 Series A Convertible Preferred Stock issuanceAction: Obtain stockholder approval at the June 23, 2026 annual meeting and finalize the asset purchase from BioInsights LLC.
Research as of 20 Jun 2026